Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Carbetocin
Overview
A long-acting synthetic analog of oxytocin with a modified disulfide bridge that confers resistance to enzymatic degradation. Carbetocin has a half-life of approximately 40 minutes compared to 3-5 minutes for oxytocin, providing sustained uterotonic activity after a single injection.
Mechanism of Action
It selectively binds oxytocin receptors in the myometrium, promoting uterine contraction and reducing postpartum blood loss.
Research Summary & Key Findings
WHO recommends heat-stable carbetocin for prevention of postpartum hemorrhage in settings where oxytocin cold chain cannot be maintained. CHAMPION trial (Widmer et al., NEJM, 2018) demonstrated non-inferiority to oxytocin for preventing blood loss at caesarean delivery. Approved in over 30 countries; not yet FDA-approved in the United States.
Clinical Status
Carbetocin is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.
Administration Routes
References
Primary literature
- PubMed: "Carbetocin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Carbetocin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Carbetocin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Reproductive
Leuprolide (Lupron)
FDA ApprovedA synthetic nonapeptide GnRH agonist approximately 15-fold more potent than native GnRH. After an initial stimulatory ph...
View detailsGoserelin (Zoladex)
FDA ApprovedA synthetic decapeptide GnRH agonist administered as a biodegradable subcutaneous implant that provides sustained drug r...
View detailsCetrorelix (Cetrotide)
FDA ApprovedA synthetic decapeptide GnRH antagonist that competitively blocks pituitary GnRH receptors, producing immediate and dose...
View detailsGanirelix
FDA ApprovedA synthetic decapeptide GnRH antagonist that competitively and reversibly blocks GnRH receptors on pituitary gonadotroph...
View detailsNo lawful pathway today
Carbetocin is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.